MX386103B - Inhibidores de mcl-1 y metodos de uso de los mismos. - Google Patents

Inhibidores de mcl-1 y metodos de uso de los mismos.

Info

Publication number
MX386103B
MX386103B MX2018012711A MX2018012711A MX386103B MX 386103 B MX386103 B MX 386103B MX 2018012711 A MX2018012711 A MX 2018012711A MX 2018012711 A MX2018012711 A MX 2018012711A MX 386103 B MX386103 B MX 386103B
Authority
MX
Mexico
Prior art keywords
methods
mcl
inhibitors
pentaazaheptacyclo
octatriaconta
Prior art date
Application number
MX2018012711A
Other languages
English (en)
Other versions
MX2018012711A (es
Inventor
Alexander Hird
Bo Peng
Daniel William Robbins
Dedong Wu
Jeffrey Johannes
John Paul Secrist
Matthew Alan Belmonte
Michelle Laurae Lamb
Qing Ye
Steven Lee Kazmirski
Wenzhan Yang
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2018012711A publication Critical patent/MX2018012711A/es
Publication of MX386103B publication Critical patent/MX386103B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se da a conocer un compuesto que es ácido 17-cloro-5,13,14,22-tetrametil-28-oxa-2,9-ditia-5,6,12,13,22-pentaazaheptaciclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaeno-23-carboxílico (fórmula I) (ver Fórmula) y enantiómeros y sales farmacéuticamente aceptables del mismo. También se dan a conocer composiciones farmacéuticas de ácido 17-cloro-5,13,14,22-tetrametil-28-oxa-2,9-ditia-5,6,12,13,22-pentaazaheptaciclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaeno-23-carboxílico, y enantiómeros y sales farmacéuticamente aceptables del mismo, y métodos de tratamiento del cáncer con tales compuestos y composiciones.
MX2018012711A 2016-04-22 2017-04-21 Inhibidores de mcl-1 y metodos de uso de los mismos. MX386103B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662326156P 2016-04-22 2016-04-22
PCT/EP2017/059511 WO2017182625A1 (en) 2016-04-22 2017-04-21 Macrocyclic mcl1 inhibitors for treating cancer

Publications (2)

Publication Number Publication Date
MX2018012711A MX2018012711A (es) 2019-05-30
MX386103B true MX386103B (es) 2025-03-18

Family

ID=58664658

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012711A MX386103B (es) 2016-04-22 2017-04-21 Inhibidores de mcl-1 y metodos de uso de los mismos.

Country Status (37)

Country Link
US (4) US9840518B2 (es)
EP (1) EP3445767B1 (es)
JP (1) JP6894449B2 (es)
KR (1) KR102388208B1 (es)
CN (1) CN109071566B (es)
AR (1) AR108301A1 (es)
AU (1) AU2017252222B2 (es)
BR (1) BR112018070677B1 (es)
CL (1) CL2018002410A1 (es)
CO (1) CO2018008759A2 (es)
CR (1) CR20180499A (es)
CY (1) CY1123186T1 (es)
DK (1) DK3445767T3 (es)
DO (1) DOP2018000222A (es)
EA (1) EA036551B1 (es)
ES (1) ES2791319T3 (es)
HR (1) HRP20200673T1 (es)
HU (1) HUE049591T2 (es)
IL (1) IL262237B (es)
LT (1) LT3445767T (es)
MA (1) MA44721B1 (es)
ME (1) ME03729B (es)
MX (1) MX386103B (es)
NI (1) NI201800093A (es)
PE (1) PE20181803A1 (es)
PH (1) PH12018502227A1 (es)
PL (1) PL3445767T3 (es)
PT (1) PT3445767T (es)
RS (1) RS60257B1 (es)
SG (1) SG11201805838UA (es)
SI (1) SI3445767T1 (es)
SM (1) SMT202000249T1 (es)
SV (1) SV2018005742A (es)
TN (1) TN2018000319A1 (es)
TW (1) TWI742074B (es)
WO (1) WO2017182625A1 (es)
ZA (1) ZA201807766B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11708391B2 (en) 2016-02-04 2023-07-25 The Johns Hopkins University Rapaglutins, novel inhibitors of GLUT and use thereof
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
EP3782636B1 (en) 2016-02-04 2024-05-15 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
JP6894449B2 (ja) 2016-04-22 2021-06-30 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 癌を治療するためのマクロ環状ｍｃｌ１阻害剤
US10981932B2 (en) 2016-05-19 2021-04-20 Bayer Aktiengesellschaft Macrocyclic indole derivatives
TW201904976A (zh) * 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Ｍｃｌ-１抑制劑及其使用方法
TWI781996B (zh) * 2017-03-31 2022-11-01 瑞典商阿斯特捷利康公司 合成ｍｃｌ-１抑制劑之方法
BR112020003130A2 (pt) * 2017-08-15 2020-10-13 AbbVie Deutschland GmbH & Co. KG inibidores macrocíclicos de mcl-1 e métodos de uso
KR20200041942A (ko) 2017-08-15 2020-04-22 애브비 인코포레이티드 거대환식 mcl-1 저해제 및 이의 용도
US11286263B2 (en) 2017-11-17 2022-03-29 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives
CN111757884B (zh) * 2017-11-17 2023-12-19 拜耳股份公司 取代的大环吲哚衍生物
US20210253598A1 (en) * 2017-11-17 2021-08-19 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
WO2019096914A1 (en) * 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
UY37973A (es) 2017-11-17 2019-06-28 Bayer Ag Derivados de indol macrocíclicos
EP3710448A1 (en) 2017-11-17 2020-09-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
TW202014184A (zh) 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
US20220041623A1 (en) 2018-09-30 2022-02-10 Jiangsu Hengrui Medicine Co., Ltd. Indole macrocyclic derivative, preparation method thereof and application thereof in medicine
TW202344250A (zh) 2018-11-14 2023-11-16 瑞典商阿斯特捷利康公司 治療癌症之方法
CN111205309B (zh) * 2018-11-21 2023-04-07 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
EP3781570A4 (en) 2018-11-22 2021-06-02 Ascentage Pharma (Suzhou) Co., Ltd. MACROCYCLIC INDOLES SERVING AS MCL-1 INHIBITORS
WO2020151738A1 (en) * 2019-01-23 2020-07-30 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic fused pyrrazoles as mcl-1 inhibitors
EP3924358A4 (en) * 2019-03-08 2023-07-05 Zeno Management, Inc. Macrocyclic compounds
CA3132530A1 (en) 2019-04-11 2020-10-15 Robert J. GARMISE Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations
TW202106693A (zh) * 2019-04-30 2021-02-16 大陸商江蘇恆瑞醫藥股份有限公司 吲哚類大環衍生物、其製備方法及其在醫藥上的應用
EA202193076A1 (ru) 2019-05-10 2022-02-16 Янссен Байотек, Инк. Макроциклические хелаторы и способы их применения
CN114127079A (zh) 2019-05-17 2022-03-01 布罗德研究所有限公司 制备大环吲哚的方法
PY2020118A (es) 2019-05-20 2022-10-27 Servier Lab Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
ES2975083T3 (es) * 2019-06-21 2024-07-03 Janssen Pharmaceutica Nv Inhibidores macrocíclicos de MCL-1
MX2022000390A (es) 2019-07-09 2022-02-10 Janssen Pharmaceutica Nv Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
US20220372014A1 (en) * 2019-10-01 2022-11-24 The Johns Hopkins University Neuroprotective compounds and methods of use thereof
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
BR112022009754A2 (pt) 2019-11-21 2022-08-09 Janssen Pharmaceutica Nv Derivados macrocíclicos de sulfonila como inibidores de mcl-1
EP4061819A1 (en) * 2019-11-21 2022-09-28 Janssen Pharmaceutica NV Macrocyclic indole derivatives as mcl-1 inhibitors
EP4051685A4 (en) * 2019-12-18 2024-01-10 Zeno Management, Inc. MACROCYCLIC COMPOUNDS
WO2021165370A1 (en) 2020-02-21 2021-08-26 Janssen Pharmaceutica Nv Macrocyclic indole derivatives as inhibitors of mcl-1
CN115335384B (zh) * 2020-03-30 2024-10-22 江苏恒瑞医药股份有限公司 一种吲哚类大环衍生物的结晶形式及其制备方法
CA3178283A1 (en) 2020-05-29 2021-12-02 Frederik Jan Rita Rombouts Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1
US20230234969A1 (en) 2020-06-19 2023-07-27 Janssen Pharmaceutica Nv N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibiors of mcl-1
CN115943146A (zh) 2020-06-19 2023-04-07 詹森药业有限公司 N-连接的大环4-(吡唑-5-基)-吲哚衍生物作为mcl-1抑制剂
CN115776888A (zh) 2020-07-08 2023-03-10 詹森药业有限公司 含大环醚的吲哚衍生物作为mcl-1抑制剂
WO2022032284A1 (en) * 2020-08-07 2022-02-10 Zeno Management, Inc. Macrocyclic compounds
CN117136076A (zh) 2020-11-24 2023-11-28 诺华股份有限公司 Mcl-1抑制剂抗体药物缀合物和使用方法
CA3200758A1 (en) 2020-12-17 2022-06-23 Janssen Pharmaceutica Nv Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1
WO2022171782A1 (en) 2021-02-12 2022-08-18 Janssen Pharmaceutica Nv Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer
WO2022251247A1 (en) * 2021-05-28 2022-12-01 Zeno Management, Inc. Macrocyclic compounds
CA3222752A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
EP4351564A1 (en) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
CN115490708B (zh) * 2021-06-18 2025-01-24 苏州亚盛药业有限公司 磺酰胺类大环衍生物及其制备方法和用途
EP4413165A1 (en) 2021-10-06 2024-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
US20250387504A1 (en) 2022-05-20 2025-12-25 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
TW202540185A (zh) 2023-11-22 2025-10-16 法商施維雅藥廠 抗cd74抗體藥物結合物及其使用方法
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682356C (en) * 2007-04-16 2016-06-14 Abbott Laboratories 7-substituted indole mcl-1 inhibitors
PL2134685T3 (pl) 2007-04-16 2016-02-29 Abbvie Inc Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1
CN102325787B (zh) * 2008-12-22 2014-05-28 丘比斯特药物股份有限公司 治疗革兰氏阳性感染的新的抗菌剂
CN102822163B (zh) * 2009-12-23 2016-01-20 艾恩伍德医药品股份有限公司 Crth2调节剂
KR101953210B1 (ko) * 2011-05-19 2019-02-28 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ 단백질 키나아제 억제제로서의 대환식 화합물
US10093640B2 (en) 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
US10005728B2 (en) 2013-08-28 2018-06-26 Vanderbilt University Substituted indole Mcl-1 inhibitors
ES2654242T3 (es) * 2014-02-12 2018-02-12 Viiv Healthcare (No.5) Limited Macrociclos de benzotiazol como inhibidores de la réplica del virus de la inmunodeficiencia humana
AU2015235944B2 (en) 2014-03-27 2020-06-25 Vanderbilt University Substituted indole Mcl-1 inhibitors
CN106459084B (zh) * 2014-04-11 2019-04-19 拜耳医药股份有限公司 大环化合物
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
JP6894449B2 (ja) 2016-04-22 2021-06-30 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 癌を治療するためのマクロ環状ｍｃｌ１阻害剤

Also Published As

Publication number Publication date
US20210230184A1 (en) 2021-07-29
TN2018000319A1 (en) 2020-01-16
EA036551B1 (ru) 2020-11-23
AR108301A1 (es) 2018-08-08
NI201800093A (es) 2019-03-14
CL2018002410A1 (es) 2018-12-07
ZA201807766B (en) 2021-09-29
EP3445767A1 (en) 2019-02-27
CY1123186T1 (el) 2021-10-29
BR112018070677B1 (pt) 2024-02-06
PT3445767T (pt) 2020-05-13
MA44721A (fr) 2019-02-27
WO2017182625A1 (en) 2017-10-26
DOP2018000222A (es) 2018-10-31
RS60257B1 (sr) 2020-06-30
IL262237A (en) 2018-11-29
IL262237B (en) 2021-08-31
US10196404B2 (en) 2019-02-05
HUE049591T2 (hu) 2020-09-28
PL3445767T3 (pl) 2020-07-13
US20180155362A1 (en) 2018-06-07
CN109071566A (zh) 2018-12-21
US10889594B2 (en) 2021-01-12
US20170305926A1 (en) 2017-10-26
US9840518B2 (en) 2017-12-12
CR20180499A (es) 2019-01-25
PE20181803A1 (es) 2018-11-19
SI3445767T1 (sl) 2020-07-31
KR102388208B1 (ko) 2022-04-18
EA201892300A1 (ru) 2019-05-31
SV2018005742A (es) 2019-03-25
ME03729B (me) 2021-01-20
CA3020378A1 (en) 2017-10-26
TW201803879A (zh) 2018-02-01
ES2791319T3 (es) 2020-11-03
HRP20200673T1 (hr) 2020-07-10
CN109071566B (zh) 2021-08-31
NZ748173A (en) 2025-05-02
PH12018502227A1 (en) 2019-07-29
DK3445767T3 (da) 2020-05-18
KR20180135030A (ko) 2018-12-19
US20190185485A1 (en) 2019-06-20
MX2018012711A (es) 2019-05-30
TWI742074B (zh) 2021-10-11
CO2018008759A2 (es) 2018-09-20
JP2019514863A (ja) 2019-06-06
AU2017252222A1 (en) 2018-11-29
LT3445767T (lt) 2020-05-25
JP6894449B2 (ja) 2021-06-30
US11472816B2 (en) 2022-10-18
SMT202000249T1 (it) 2020-07-08
AU2017252222B2 (en) 2019-11-07
EP3445767B1 (en) 2020-02-19
MA44721B1 (fr) 2020-05-29
SG11201805838UA (en) 2018-11-29
BR112018070677A2 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
MX386103B (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
JOP20190174B1 (ar) مثبطات jak1 انتقائية
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
MX2020007265A (es) Derivados de rapamicina.
MX377124B (es) Compuestos heterociclicos y usos de los mismos.
MX386089B (es) Compuesto heterociclico utilizado como inhibidor de fgfr.
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
EA201792259A1 (ru) Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения
EA201691302A1 (ru) Новые гетероциклические соединения
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
NZ726608A (en) Phosphatidylinositol 3-kinase inhibitors
NZ726052A (en) Phosphatidylinositol 3-kinase inhibitors
MX390747B (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
NZ726360A (en) Phosphatidylinositol 3-kinase inhibitors
NZ726055A (en) Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
EA201692300A1 (ru) Производные карбоксамида
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
MX2018015990A (es) Compuestos terapeuticos.
EA202190989A1 (ru) Новый способ синтеза производных пиперазинил-этокси-бромфенила и их применение в получении содержащих их соединений
EA201992153A1 (ru) Гетероарилтрифторборатные соединения для лечения микобактериальных инфекций